Secretion of fibronectin by human pancreatic stellate cells promotes chemoresistance to gemcitabine in pancreatic cancer cells

[1] Kamisawa T(2016)Pancreatic cancer Lancet 388 73-85

[2] Wood LD(2016)Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol 55 259-264

[3] Itoi T(2016)Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev 30 355-385

[4] Takaori K(2016)Pancreatic cancer Nat Rev Dis Primers 2 16022-2921

[5] Zijlstra M(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-277

[6] Bernards N(2016)Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study Acta Oncol 55 265-348

[7] de Hingh IH(2018)Therapeutic developments in pancreatic cancer: current and future perspectives Nat Rev Gastroenterol Hepatol 15 333-2413

[8] van de Wouw AJ(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-88

[9] Goey SH(2009)Clinical pharmacology and pharmacogenetics of gemcitabine Drug Metab Rev 41 77-1285

[10] Jacobs EM(2017)Pancreatic Cancer Chemoresistance to Gemcitabine Cancers 9 157-868

[1] Kamisawa T(2016)Pancreatic cancer Lancet 388 73-85

[2] Wood LD(2016)Does long-term survival exist in pancreatic adenocarcinoma? Acta Oncol 55 259-264

[3] Itoi T(2016)Genetics and biology of pancreatic ductal adenocarcinoma Genes Dev 30 355-385

[4] Takaori K(2016)Pancreatic cancer Nat Rev Dis Primers 2 16022-2921

[5] Zijlstra M(2014)Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States Cancer Res 74 2913-277

[6] Bernards N(2016)Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - a population-based cohort study Acta Oncol 55 265-348

[7] de Hingh IH(2018)Therapeutic developments in pancreatic cancer: current and future perspectives Nat Rev Gastroenterol Hepatol 15 333-2413

[8] van de Wouw AJ(1997)Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial J Clin Oncol 15 2403-88

[9] Goey SH(2009)Clinical pharmacology and pharmacogenetics of gemcitabine Drug Metab Rev 41 77-1285

[10] Jacobs EM(2017)Pancreatic Cancer Chemoresistance to Gemcitabine Cancers 9 157-868